|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | MST-104, NSC 213841, SLC-0111, WBI-5111 | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||||||
| 化学式 | C13H12FN3O3S |
||||||||||
| 分子量 | 309.32 | CAS No. | 178606-66-1 | ||||||||
| Solubility (25°C)* | 体外 | DMSO | 31 mg/mL (100.21 mM) | ||||||||
| Water | Insoluble | ||||||||||
| Ethanol | Insoluble | ||||||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||||||
| 製品説明 | U-104 (MST-104, NSC 213841, SLC-0111, WBI-5111) is a potent carbonic anhydrase (CA) inhibitor for CA IX and CA XII with Ki of 45.1 nM and 4.5 nM, respectively, very low inhibition for CA I and CA II. |
|---|---|
| in vitro | U-104 (50 μM) blocks the mesenchymal phenotype in the cancer stem cells population in hypoxia condition of 4T1 cells. This compound (<50 μM) significantly reduces migration in a dose-dependent manner in metastatic MDA-MB-231 LM2-4Luc+ cells , with cells growing as compact colonies similar to parental MDA-MB-231 cells. [2] This chemical possesses aromatic groups at the second nitrogen ureido group. [3] |
| in vivo | U-104 (38 mg/kg) inhibits primary tumor growth in the mice implanted orthotopically with MDA-MB-231 LM2-4Luc+ cells. This compound (19 mg/kg) inhibits metastases formation in the 4T1 experimental metastasis mice model. [1] This chemical (38 mg/kg) significantly delay primary tumor growth and reduces cancer stem cell population in NOD/SCID mice orthotopically implanted with MDA-MB-231 LM2-4Luc+ cells. It (5 mg/mL, oral gavage) shows a significant delay in tumor growth in Balb/c mice orthotopically implanted with 4T1 cells. [2] |
| 動物実験 | 動物モデル | Balb/c mice orthotopically implanted with 4T1 cells. |
|---|---|---|
| 投薬量 | 5 mg/mL | |
| 投与方法 | Oral gavage |
|

, , Lab Invest, 2016, 96(12):1234-1245

Data from [Data independently produced by , , Sci Rep, 2015, 5:14508]

Data from [Data independently produced by , , Int J Oncol, 2018, 53(1):189-202]
| Alterations in gene expression associated with invasion of RAS-mutant thyroid tumors and their potential diagnostic and therapeutic utility [ Eur Thyroid J, 2025, 14(3)e250022] | PubMed: 40440326 |
| Depletion of slow-cycling PDGFRα+ADAM12+ mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis [ Nat Immunol, 2023, 24(11):1867-1878] | PubMed: 37798557 |
| SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration [ Front Oncol, 2023, 13:1118268] | PubMed: 36776327 |
| CA9 and PRELID2; hypoxia-responsive potential therapeutic targets for pancreatic ductal adenocarcinoma as per bioinformatics analyses [ J Pharmacol Sci, 2023, 10.1016/j.jphs.2023.10.003] | PubMed: 37973221 |
| A nanoplatform to boost multi-phases of cancer-immunity-cycle for enhancing immunotherapy [ J Control Release, 2021, 339:403-415] | PubMed: 34655676 |
| Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities. [ Cell Rep, 2020, 14;31(2):107509] | PubMed: 32294439 |
| Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment [ Cancers (Basel), 2020, 12(9)E2697] | PubMed: 32967224 |
| One-pot synthesis of pH-responsive charge-switchable PEGylated nanoscale coordination polymers for improved cancer therapy [Yang Y, et al. Biomaterials, 2018, 156:121-133] | PubMed: 29195181 |
| Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ [Xu X, et al. Int J Oncol, 2018, 53(1):189-202] | PubMed: 29749469 |
| Activation of carbonic anhydrase IX by alternatively spliced tissue factor under late-stage tumor conditions [Ramchandani D, et al. Lab Invest, 2016, 10.1038/labinvest.2016.103] | PubMed: 27721473 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。